Merck Patent Gmbh

Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Medice Arzneimittel Pütter Gmbh & Co. Kg

Florian Lang

Norbert Beier

Rolf Gericke

Werner Mederski

Markus Klein

Dieter Dorsch

Lars Thore Burgdorf

Thomas Fuchss

Phillipp Lang

Siegfried Waldegger

Angelika Lampert

Hannsjoerg Seybert

Nikola Jeck

Karl Lang

Ulrich Graedler

Philipp Lang

Oliver Poeschke

Helga Drosdat

Novel heterocyclic compounds of the formula (I), in which R, D, W, T and T' have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Heterocyclic carbonyl compounds

The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.

SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas

Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R, R, R, R, R, Rand Rhave the meanings indicated in claim, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases.

Difluorophenyldiacylhydrazide derivatives

Novel oxadiazole derivatives of the formula (I), in which R, R', Y, X, Xand Xhave the meanings indicated in claim, are kinase inhibitors and can be used for the treatment of diseases and conditions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, in general in all types of fibroses, inflammatory processes, tumours and tumour diseases.

Oxadiazole derivatives for the treatment of diabetes

Novel aminoindazolylurea derivatives of the formula I (I), in which R, R, R, R, R, X and Y have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Aminoindazolylurea derivatives

The invention relates to novel indazole derivatives as cited in claim, which are inhibitors of CHK1, CHK2 and SGK kinases and can be used to treat cancer and other diseases.

Indazole-heteroaryl derivatives

Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type. 

3-aminoindazoles

Novel mandelic hydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Mandelic hydrazides

Novel acyl hydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type. 

Acyl hydrazines as kinase inhibitors, in particular for SGK

Novel ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acetohydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides

The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: Rand Rindependently of one another represent H, OH, OA, OAc or methyl; R, R, R, R, R, R, Rand Rindependently of one another represent H, OH, OA, OAc, OCF, Hal, NO, CF, A, CN, OSOCH, SOCH, NH, or COOH; Rrepresents H or CH; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH, CHCH, OCHor &#x2014;CH(OH)&#x2014; and Hal represents F, Cl, Br or I. 

Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction

The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid positioncompared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.

CICKb mutation as a diagnostic and therapeutical target

The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid positioncompared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.

Growing community of inventors

Tuebingen, Germany

Florian Lang